The Evidence Brief

How a supplement brand's calming claim fell apart under regulatory review

Alice Mushrooms had to narrow its Zen-X claim to the one ingredient that had been tested at the same dose as the product.

Alice Mushrooms sells functional mushroom chocolates built around specific states, energy, focus, sleep, stress relief, with its Zen-X line aimed at calm. The National Advertising Division ruled this month that the brand couldn't support Zen-X's claim, "cool, calm and collected is one delicious bite away," using separate studies on the three ingredients behind it. NAD found the evidence on L-theanine and kanna extract wasn't a good fit for the benefits being claimed, and that stacking ingredient studies together doesn't show how those ingredients behave combined in the finished formula. Only the saffron claim survived, because one clinical study had tested saffron at the same dose as in Zen-X and found statistically significant results on tension, stress and vigour. Alice Mushrooms has to narrow its claim to saffron alone, and during the case it also dropped the rest of its claims on Zen-X and all of them on Brainstorm.

The only claim NAD upheld was backed by a study testing saffron at the exact same dose as in the product.

NAD's assistant director Annie M. Ugurlayan said the decision was consistent with the regulator's precedent, that there needs to be a good fit between the claims and the support behind them. An advertiser making a performance claim generally needs reliable testing on the product itself, she said, though that doesn't always mean a clinical trial on every finished formulation. Ingredient research can stand in for that in limited circumstances, but NAD weighs the population studied, the dose tested, how it was taken, and whether the results are large enough to matter to a consumer, not just statistically significant.

Our read

This is where the saffron result is actually the more useful story than the rejection. The reason it survived comes down to a basic principle of good evidence, the study tested saffron at the same dose as the product, on the same outcomes being promised. That's what proof a product works looks like, and it's proof that held up under regulatory scrutiny. What tripped up the rest came from the more common shortcut, stitching together three separate studies on three separate ingredients and treating that as proof the finished formula works, when nobody had tested how those three ingredients behave together.

That's the opportunity as much as the warning. An ingredient supplier that commissions a dose-matched study on its own ingredient, the way saffron was tested here, hands its brand customers evidence that actually survives scrutiny, and gives itself a real point of difference over suppliers offering only a shelf of loosely related citations. A brand that goes a step further and tests its own finished formula gets to make the claim outright, rather than relying on someone else's ingredient study and hoping the gap doesn't get noticed. The research here clearly can back a claim, it just has to be the right research, at the right dose, on the right thing.

Sources: Ni on the NAD ruling, NAD case summary via BBB National Programs

Get The Evidence Brief

Industry news filtered down to the stories that show how health brands use science to win, every other Wednesday.

Subscribe